IRIS
FORCONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.704
EU - Europa 5.528
AS - Asia 1.050
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 10
AF - Africa 6
Totale 17.326
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.687
GB - Regno Unito 1.656
IE - Irlanda 1.051
CN - Cina 846
UA - Ucraina 834
SE - Svezia 456
FR - Francia 362
RU - Federazione Russa 345
DE - Germania 292
IT - Italia 280
FI - Finlandia 172
SG - Singapore 119
VN - Vietnam 29
CA - Canada 15
NL - Olanda 14
TR - Turchia 14
BE - Belgio 13
EU - Europa 11
CZ - Repubblica Ceca 10
AU - Australia 9
HR - Croazia 9
IN - India 7
CL - Cile 6
BR - Brasile 5
JP - Giappone 5
AR - Argentina 4
HK - Hong Kong 4
LT - Lituania 4
AL - Albania 3
CI - Costa d'Avorio 3
EG - Egitto 3
ES - Italia 3
ID - Indonesia 3
IL - Israele 3
IR - Iran 3
LU - Lussemburgo 3
MY - Malesia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BG - Bulgaria 2
DK - Danimarca 2
EE - Estonia 2
GR - Grecia 2
KG - Kirghizistan 2
KR - Corea 2
PL - Polonia 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CH - Svizzera 1
EC - Ecuador 1
GE - Georgia 1
JM - Giamaica 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SI - Slovenia 1
Totale 17.326
Salva come PNG Salva come JPEG
Città #
Fairfield 2.228
Southend 1.525
Dublin 1.049
Ashburn 1.037
Woodbridge 1.016
Seattle 891
Houston 781
Wilmington 767
Cambridge 739
Jacksonville 676
Chandler 582
Ann Arbor 378
Princeton 232
Nanjing 220
Siena 194
Beijing 155
San Diego 86
Nanchang 85
Boardman 83
Singapore 75
Moscow 74
Shenyang 61
San Mateo 43
Hebei 42
London 34
Changsha 33
Jiaxing 33
Norwalk 32
Shanghai 32
Helsinki 30
Dong Ket 29
Falls Church 29
Tianjin 28
Kunming 26
Menlo Park 23
Düsseldorf 22
New York 21
Ningbo 20
San Francisco 19
Jinan 16
Zhengzhou 16
Hangzhou 15
Brussels 13
Toronto 12
Taizhou 10
Fremont 9
Guangzhou 9
Hounslow 9
Washington 9
Zagreb 9
Haikou 8
Changchun 7
Edinburgh 7
Renton 7
Brno 6
Chiswick 6
Detroit 6
Lancaster 6
Amsterdam 5
Groningen 5
Indiana 5
Izmir 5
Kilburn 5
Los Angeles 5
São Paulo 5
Venezia 5
Chicago 4
Lanzhou 4
Mestre 4
Milan 4
New Bedfont 4
Prague 4
Redwood City 4
Rome 4
Santa Clara 4
Sydney 4
Abidjan 3
Acton 3
Annecy 3
Canberra 3
Colle Di Val D'elsa 3
Dallas 3
Dearborn 3
Kalyān 3
Luxembourg 3
Paris 3
Phoenix 3
Piacenza 3
Prescot 3
Redmond 3
Tappahannock 3
Tashkent 3
Tirana 3
Tokyo 3
Berzo Inferiore 2
Bishkek 2
Bratislava 2
Cairo 2
Central 2
Cherbourg-Octeville 2
Totale 13.756
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. 211
BRAF mutations in hairy-cell leukemia. 176
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. 176
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction. 170
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 169
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 168
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 167
The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. 166
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 164
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia. 164
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 164
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. 164
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 163
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 162
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 162
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. 160
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 159
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 158
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 155
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 155
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 155
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. 153
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 153
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 152
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 151
Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing 151
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. 151
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. 150
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis 149
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. 148
Emerging drugs in chronic myelogenous leukaemia 146
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 146
Towards the pharmacotherapy of hairy cell leukaemia 145
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. 145
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 144
Predicting the clinical course of Hodgkin lymphoma 144
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. 143
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. 143
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 143
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 143
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort 142
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation 142
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 142
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK 142
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. 141
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. 141
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 139
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. 138
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. 137
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia 137
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism 137
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. 136
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. 135
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. 135
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. 135
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. 135
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 134
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. 133
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses 133
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 133
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. 132
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 131
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. 131
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 130
Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes 130
IL-4 enhances expression and function of surface IgM in CLL cells 130
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. 129
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 127
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. 127
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia 125
Alternative methods of cladribine administration. 124
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 124
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 123
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 122
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 121
Three years of ibrutinib in CLL 121
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. 120
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 119
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition 119
PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis 118
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 118
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity 116
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. 114
The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia 113
null 113
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. 112
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 112
Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. 112
Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL 111
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function 110
Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia 110
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy 110
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 109
Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey 109
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: Proliferation or anergy 109
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 108
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide 108
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. 107
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. 107
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia 106
Totale 13.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.239 0 0 363 880 357 375 433 620 469 379 96 267
2020/20212.870 129 354 100 300 176 330 138 412 283 260 225 163
2021/20221.630 112 265 56 104 73 60 87 51 89 204 172 357
2022/20232.166 162 123 321 300 229 459 35 164 253 25 60 35
2023/20241.355 72 35 71 125 34 389 473 6 7 16 9 118
2024/2025472 93 178 201 0 0 0 0 0 0 0 0 0
Totale 17.441